Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry

Atopic Dermatitis

The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: results from a placebo-controlled, phase 3 study

J Am Acad Dermatol

Paller AS, Silverberg JI, Simpson EL, Cork MJ, Arkwright PD, Chen Z, Bansal A, Prescilla R, Wang Z, Marco AR

doi: 10.1016/j.jaad.2024.09.039

Atopic Dermatitis

Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study

JAMA Dermatol

Beck LA, Bissonnette R, Deleuran M, Nakahara T, Galus R, Coleman A, Gherardi G, Xiao J, Dingman R, Xu C, Avetisova E, Dubost-Brama A, Shabbir A

doi: 10.1001/jamadermatol.2024.1536

Atopic Dermatitis

A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register

Br J Dermatol

Alexander H, Malek R, Prieto-Merino D, Gribaleva E, Baden M, Beattie P, Brown S, Burton T, Cameron S, Coker B, Cork MJ, Hearn R, Ingram JR, Irvine AD, Johnston GA, Lambert A, Lunt M, Man I, Newell L, Ogg G, Patel P, Wan M, Warren RB, Woolf R, Yiu ZZN, Reynolds N, Ardern-Jones MR, Flohr C, UK-Irish A-STAR Study Group

doi: 10.1093/bjd/ljae287

Atopic Dermatitis

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Week 16 results of an Open-label, Randomized, Efficacy Assessor-Blinded Head-to-Head Phase 3b/4 Study (Level Up)

Br J Dermatol

Silverberg JI, Bunick CG, Hong HC, Mendes-Bastos P, Stein Gold L, Costanzo A, Ibrahim N, Sancho C, Wu X, Han Y, Levy G, Altman K, Calimlim B, Eyerich K

doi: 10.1093/bjd/ljae404

Atopic Dermatitis

Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study

Acta Derm Venereol

Calabrese L, Cinotti E, D'Onghia M, Cartocci A, Rubegni P, Maccari F, Boulard C, Reguiai Z, Becherel PA, Jacobzone C, Begon E, Fite C, Walls B, Liegeon AL, Parier J, Chaby G, Perrot JL, Omcci Group

doi: 10.2340/actadv.v105.42275

Atopic Dermatitis

Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Moderate to Severe Atopic Dermatitis in Adults and Children Down to 2 Years of Age in the Pivotal Phase 3 ADORING Trials

J Am Acad Dermatol

Silverberg JI, Eichenfield LF, Hebert AA, Simpson EL, Stein Gold L, Bissonnette R, Papp KA, Browning J, Kwong P, Korman NJ, Brown PM, Rubenstein DS, Piscitelli SC, Somerville MC, Tallman AM, Kircik L

doi: 10.1016/j.jaad.2024.05.023

Atopic Dermatitis

Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials

Adv Ther

Ständer S, Yosipovitch G, Simpson EL, Kim BS, Kabashima K, Thaçi D, Metz M, Chen Z, Hagen S, Bastian M

doi: 10.1007/s12325-025-03124-8

Atopic DermatitisAllergic Diseases

Patient-Reported Outcome Measures in Atopic Dermatitis and Chronic Urticaria are Underused in Clinical Practice

J Allergy Clin Immunol Pract

Cherrez-Ojeda I, Bousquet J, Giménez-Arnau A, Godse K, Krasowska D, Bartosińska J, Szczepanik-Kułak P, Wawrzycki B, Kolkhir P, Allenova A, Allenov A, Tkachenko S, Teovska Mitrevska N, Mijakoski D, Stoleski S, Kolacinska-Flont M, Kuprys-Lipinska I, Molinska J, Kasperska-Zając A, Zajac M, Zamlynski M, Mihaltan F, Ulmeanu R, Zalewska-Janowska A, Tomaszewska K, Al-Ahmad M, Al-Nesf MA, Ibrahim T, Aqel S, Pesqué D, Rodríguez-González M, Wakida-Kuzunoki GH, Ramon GD, Ramon GN, Neisinger S, Bonnekoh H, Rukhadze M, Khoshkhui M, Fomina D, Larenas-Linnemann D, Košnik M, Oztas Kara R, Caballero López CG, Liu Q, Ivancevich Juan C, Ensina LF, Rosario N, Kvedariene V, Ben-Shoshan M, Criado RFJ, Bauer A, Cherrez A, Chong-Neto H, Rojo-Gutierrez MI, Rudenko M, Larco Sousa JI, Lesiak A, Matos E, Muñoz N, Tinoco I, Moreno J, Crespo Shijin C, Hinostroza Logroño R, Sagñay JC, Faytong-Haro M, Robles-Velasco K, Zuberbier T, Maurer M

doi: 10.1016/j.jaip.2024.03.050

Atopic Dermatitis

One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis

Adv Ther

Calzavara-Pinton P, Chu CY, Lapeere H, Rossi M, Ferrucci SM, Chung WH, Fougerousse AC, Fomina DS, Holzer G, Čelakovská J, Al-Ahmad M, Tzellos T, Wu J, Ardeleanu M, Bosman K

doi: 10.1007/s12325-024-03049-8

Related content

The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: results from a placebo-controlled, phase 3 study

Dupilumab in Adults With Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study

A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Week 16 results of an Open-label, Randomized, Efficacy Assessor-Blinded Head-to-Head Phase 3b/4 Study (Level Up)

Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study

Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Moderate to Severe Atopic Dermatitis in Adults and Children Down to 2 Years of Age in the Pivotal Phase 3 ADORING Trials

Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials

Patient-Reported Outcome Measures in Atopic Dermatitis and Chronic Urticaria are Underused in Clinical Practice

One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis